10-Q quarterly report · filed Nov 12, 2026

Candel Therapeutics, Inc. (CADL) Q3 2026 10-Q Quarterly Report

Short answer

Candel Therapeutics, Inc. (CADL) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$22M
−94.1% YoY · +43.8% QoQ
EPS (diluted)
−$0.28
−27.3% YoY · +50.0% QoQ

Source: XBRL data from the Candel Therapeutics, Inc. (CADL) Q3 2026 10-Q on SEC EDGAR. USD.

Candel Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales generated
  • Net loss $21.9M vs $11.3M YoY, operating expenses $23.0M vs $13.2M
  • R&D highest spending line: $15.6M vs $8.5M, driven by aglatimagene development
  • Cash and equivalents $203.1M, operating cash use $58.3M, financing cash inflow $142.6M
  • Outlook: cash runway into Q2 2028, additional capital required for NSCLC phase 3 and commercialization preparation

Risk Factors

  • Newly added regulatory risk: June 2026 FDA guidance may require additional clinical data despite a single-trial approval pathway
  • Most material financial update: $203.1 million cash expected to fund operations into Q2 2028
  • Debt risk: Trinity facility totals $130.0 million, with $50.0 million outstanding and covenant-triggered acceleration possible
  • Near-term operational risk: Small eligible brain-cancer population may delay linoserpaturev trial enrollment
  • Compliance risk: GDPR violations may trigger fines up to €20 million or 4% of annual global revenues

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Candel Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.